View Profile

General information

Company profile	m-lab GmbH is a German biotech company, founded in 2014, with ties to some highly regarded research institutions, initially dedicated to the development of LFA for POC diagnosis of eye diseases, including glaucoma, antibody-based treatments and reader software development. Our goal is to prevent blindness caused by glaucoma. We are committed to commercialize a glaucoma diagnostic platform that will provide the general population easy, affordable and widespread access to disease detection and early treatment initiation. Initially focusing on glaucoma, we are presently expanding our research interests to include other targets and other pathologies, using our unique multiplex platform, which can detect disease-specific marker patterns in various body fluids. Our “microarray on the strip” is fast and cost-effective, has a high accuracy and allows the simultaneous detection of two or more antigens with mobile phone-based analysis for point-of-care target quantification and/or diagnosis.
Products & Services	Our Glaucoma diagnostic platform will provide early detection of Glaucoma, the most prevalent cause of blindness in the world today, yielding a Glaucoma Risk Score within a few minutes independent from specialized labs. The POC test is based on highly sensitive multiplexing lateral flow platform detecting disease specific marker patterns in tear fluid with a reader and combined smartphone software for A.I. based disease scoring and reaches sensitivity and specificity of > 90% in glaucoma detection. Patents are already granted in all large market countries e.g. USA, China, Europe, Japan. In parallel, we are continuously developing our therapeutic antibody program, with the aim of developing urgently needed new neuroprotective treatment options and could show extraordinary therapeutic effect of antibody treatment in glaucoma animal model and eye explants. We provide third party production of LFA and contract research for customized rapid test development for detection of disease markers.
References and export activities	Lateral flow assay for monitoring COVID vaccination protection (on the market in Japan)
Target group	Ophthalmologists recommend annual glaucoma examination for high-risk individuals (all people 50+). We foresee a yearly screening test for all people aged 50+ years. Our test delivers reliable results within minutes and can be used by opticians, family doctors or pharmacists. No need for specialized labs and independent of ophthalmologists. Ideal for OCT retailing, which required big investments in device and staff.
Competitive advantages	Glaucoma LFA: Fast, easy to use POC device compared to standard diagnostic devices (e.g. OCT) Independency from specialized laboratories, enabling yearly screening tests for reliable and easy diagnosis, risk profiling for progression. Proprietary technology for multiplexing LFA. Innovative system for the detection of targets in tears and other body fluids. Software and hardware for the optical analysis of multiplex systems
Ideal Business Partners	Are you interested in developing a LFA with Multiplex and Signal Analysis systems? We provide third party production of LFA and contract research for customized rapid test development for detection of disease markers. We seek financial investment partners (e.g. VC and M+A), and licensing/distribution options for our glaucoma LFA, as a simple rapid test that provides a glaucoma risk score within minutes.